Upper GI
MULTI-001 Nivolumab v11
MULTI-002 Carboplatin and etoposide v1
MULTI-003 Pembrolizumab v11
MULTI-014 Irinotecan & Capecitabine v1
MULTI-018 Larotrectinib v2
MULTI-019 Entrectinib v2
MULTI-021 Carboplatin and paclitaxel v1
MULTI-026 Trifluridine & Tipiracil (Lonsurf®) v1
MULTI-027 Cabozantinib (Cabometyx®) v1
MULTI-028 Regorafenib v2
MULTI-032 OXALIPLATIN & MOD de GRAMONT v1
UGI-005 CF without radiotherapy v6
UGI-006 CX without radiotherapy v6
UGI-007 CARBO X v5
UGI-008 CarboF v6
UGI-023 Sorafenib v7
UGI-036 CARBOPLATIN and PACLITAXEL with radiotherapy v4
UGI-037 DCF v3
UGI-039 Modified Folfirinox (palliative) v5
UGI-040 Everolimus NET v4
UGI-047 Nab-Paclitaxel (Abraxane) ® Gemcitabine v6
UGI-052 CarboX & Trastuzumab IV v2
UGI-053 CarboF & Trastuzumab IV v1
UGI-055 GEMCITABINE & CARBOPLATIN v3
UGI-058 FLOT v3
UGI-059 Capecitabine for resected biliary tract cancer v1
UGI-060 Lenvatinib (LENVIMA®) v2
UGI-061 Folfirinox (adjuvant) v1
UGI-062 OX (reduced dose) v1
UGI-066 Atezolizumab (SC) and Bevacizumab v4
UGI-067 Pemigatinib v2
UGI-069 Pembrolizumab in combination with chemotherapy v3
UGI-070 OX (standard dose, continuous capecitabine) v1
UGI-071 CF (Chemoradiation – based on SCOPE2) v2
UGI-072 CX (Chemoradiation – based on SCOPE2) v1
UGI-073 OX (standard dose, continuous capecitabine) and trastuzumab IV v1
UGI-074 Nivolumab in combination with chemotherapy v3
UGI-075 CarboF (Chemoradiation – based on SCOPE2) v1
UGI-076 Carbo X (Chemoradiation – based on SCOPE2) v2
UGI-077 Durvalumab with Gemcitabine and cisplatin v1
UGI-078 Ivosidenib v1
MULTI-002 Carboplatin and etoposide v1
MULTI-003 Pembrolizumab v11
MULTI-014 Irinotecan & Capecitabine v1
MULTI-018 Larotrectinib v2
MULTI-019 Entrectinib v2
MULTI-021 Carboplatin and paclitaxel v1
MULTI-026 Trifluridine & Tipiracil (Lonsurf®) v1
MULTI-027 Cabozantinib (Cabometyx®) v1
MULTI-028 Regorafenib v2
MULTI-032 OXALIPLATIN & MOD de GRAMONT v1
UGI-006 CX without radiotherapy v6
UGI-007 CARBO X v5
UGI-008 CarboF v6
UGI-023 Sorafenib v7
UGI-036 CARBOPLATIN and PACLITAXEL with radiotherapy v4
UGI-037 DCF v3
UGI-039 Modified Folfirinox (palliative) v5
UGI-040 Everolimus NET v4
UGI-047 Nab-Paclitaxel (Abraxane) ® Gemcitabine v6
UGI-052 CarboX & Trastuzumab IV v2
UGI-053 CarboF & Trastuzumab IV v1
UGI-055 GEMCITABINE & CARBOPLATIN v3
UGI-058 FLOT v3
UGI-059 Capecitabine for resected biliary tract cancer v1
UGI-060 Lenvatinib (LENVIMA®) v2
UGI-061 Folfirinox (adjuvant) v1
UGI-062 OX (reduced dose) v1
UGI-066 Atezolizumab (SC) and Bevacizumab v4
UGI-067 Pemigatinib v2
UGI-069 Pembrolizumab in combination with chemotherapy v3
UGI-070 OX (standard dose, continuous capecitabine) v1
UGI-071 CF (Chemoradiation – based on SCOPE2) v2
UGI-072 CX (Chemoradiation – based on SCOPE2) v1
UGI-073 OX (standard dose, continuous capecitabine) and trastuzumab IV v1
UGI-074 Nivolumab in combination with chemotherapy v3
UGI-075 CarboF (Chemoradiation – based on SCOPE2) v1
UGI-076 Carbo X (Chemoradiation – based on SCOPE2) v2
UGI-077 Durvalumab with Gemcitabine and cisplatin v1
UGI-078 Ivosidenib v1